出版：Market Research Future（マーケットリサーチフューチャー） 出版年月：2022年10月
Global Neuropathic Pain Market Research Report Forecast to 2027
世界の神経障害性疼痛市場調査レポート : 2027年までの予測
| ページ数 | 208 |
| 価格 | |
| シングルユーザライセンス | USD4,950 |
| エンタープライズライセンス | USD7,250 |
| 種別 | 英文調査報告書 |
Global Neuropathic Pain Market Research Report – Forecast to 2027
Market analysis
Neuropathic Pain Market is anticipated to surpass USD 28,778.20 million by 2027 at a notable CAGR of 6.3% during the review period.
Neuropathic pain is prominently caused by the peripheral nerve disorder. The global market growth is attributed to the introduction of pain management centers along with higher demand for generic drugs.
In Neuropathic Pain Market, diabetes is one of the main sources of expanded neuropathic torment. The subsequent primary driver of neuropathic torment is the destructive infection called disease. According to World Health Organization (WHO) reports, in 2014, there were around 422 million individuals who were experiencing diabetes.
The huge populace is likewise viewed as one of the essential basic drivers of the market. Likewise, better treatment offices, improvement of medical care frameworks, ascend popularity of neuropathic torment and critical ventures by pharma organizations, improvement in nature of medications, and quantities of torment the board frameworks will push the market on a positive course.
Market segmentation
Based on type segment, the global neuropathic pain market has been classified into peripheral neuropathy, post-traumatic neuropathy, post-herpetic neuralgia (PHN), phantom limb pain, entrapment neuropathy, and trigeminal neuralgia. Based on indication, the market is divided into chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and spinal stenosis. In terms of diagnosis, the market is segmented into blood tests, imaging, and physical examination. Based on its treatment, the market is classified into medication type and multimodal therapy. The end-use industries include clinics, hospitals, and research organizations. Based on its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.
Regional analysis
The nations in North America and South America contained an all-out market esteem worth of USD 6,645.09 million in the year 2019. It is anticipated that it will arrive at a CAGR of around 5.6% during the gauge time frame. The rising number of problems connected with neuropathic torment, mechanical turns of events, and ascend in mindfulness are the fundamental elements of the Neuropathic Pain Market development.
The American market is grouped into North America and Latin America. The market of North America is additionally partitioned into the United States of America and Canada.
The neuropathic torment market in Western Europe has been isolated into France, the UK, Germany, Spain, Italy, and other European nations. The market in Asia-Pacific is sectioned into India, Japan, Australia, China, South Korea, and different nations in the Asia-Pacific area. The Market in the Middle East and African district is separated into the Middle East and Africa.
Major players
Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others, are some of the major players in the global neuropathic pain market.
目次
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION 22
2.2 SCOPE OF THE STUDY 22
2.3 RESEARCH OBJECTIVE 22
2.4 MARKET STRUCTURE 23
2.5 ASSUMPTIONS & LIMITATIONS 24
3 RESEARCH METHODOLOGY
3.1 DATA MINING 25
3.2 SECONDARY RESEARCH 26
3.3 PRIMARY RESEARCH 27
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 28
3.5 FORECASTING TECHNIQUES 29
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30
3.6.1 BOTTOM-UP APPROACH 31
3.6.2 TOP-DOWN APPROACH 31
3.7 DATA TRIANGULATION 32
3.8 VALIDATION 32
4 MARKET DYNAMICS
4.1 OVERVIEW 33
4.2 DRIVERS 34
4.2.1 RISING PREVALENCE OF DIABETIC NEUROPATHY 34
4.2.2 INCREASING HEALTHCARE EXPENDITURE 34
4.2.3 GROWING NUMBER OF INCIDENCE OF TRAUMA FROM INJURY AND OTHER CONDITIONS 35
4.3 RESTRAINTS 36
4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE THERAPEUTIC TREATMENT 36
4.3.2 LACK OF AWARENESS ABOUT THE NEUROLOGICAL CONDITION 37
4.4 OPPORTUNITIES 38
4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS 38
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 39
5.1.1 R&D 40
5.1.2 MANUFACTURING 40
5.1.3 DISTRIBUTION AND SALES 40
5.1.4 POST-SALES MONITORING 40
5.2 PORTER’S FIVE FORCES MODEL 41
5.2.1 BARGAINING POWER OF SUPPLIERS 42
5.2.2 BARGAINING POWER OF BUYERS 42
5.2.3 THREAT OF NEW ENTRANTS 42
5.2.4 THREAT OF SUBSTITUTES 42
5.2.5 INTENSITY OF RIVALRY 42
5.3 IMPACT ANALYSIS OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET 43
5.3.1 OVERVIEW 43
5.3.2 IMPACT ON ONGOING TREATMENTS AND DELAYED AVAILABILITY DUE TO DEFERMENT 43
5.3.3 IMPACT ON NUMBER OF PATIENTS 44
6 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE
6.1 OVERVIEW 45
6.2 PERIPHERAL NEUROPATHY 47
6.3 ENTRAPMENT NEUROPATHY 47
6.4 TRIGEMINAL NEURALGIA 48
6.5 PHANTOM LIMB PAIN 48
6.6 POST HERPETIC NEURALGIA (PHN) 49
6.7 POST TRAUMATIC NEUROPATHY 49
7 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION
7.1 OVERVIEW 50
7.2 DIABETIC NEUROPATHY 52
7.3 SPINAL STENOSIS 52
7.4 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY 53
7.5 OTHERS 53
8 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS
8.1 OVERVIEW 54
8.2 IMAGING 55
8.3 BLOOD TESTS 56
8.4 PHYSICAL EXAMINATION 56
9 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT
9.1 OVERVIEW 57
9.2 MEDICATION 58
9.3 MULTIMODAL THERAPY 60
10 GLOBAL NEUROPATHIC PAIN SMARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW 61
10.2 RETAIL PHARMACIES & DRUG STORES 62
10.3 ONLINE PHARMACIES 62
11 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER
11.1 OVERVIEW 63
11.2 HOSPITALS 64
11.3 CLINICS 64
11.4 RESEARCH ORGANIZATIONS 65
12 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION
12.1 OVERVIEW 66
12.2 AMERICAS 67
12.2.1 NORTH AMERICA 72
12.2.1.1 US 77
12.2.1.2 CANADA 81
12.2.2 LATIN AMERICA 85
12.3 EUROPE 90
12.3.1 WESTERN EUROPE 95
12.3.1.1 GERMANY 100
12.3.1.2 UK 104
12.3.1.3 FRANCE 108
12.3.1.4 ITALY 112
12.3.1.5 SPAIN 116
12.3.1.6 REST OF WESTERN EUROPE 120
12.3.2 EASTERN EUROPE 124
12.4 ASIA-PACIFIC 129
12.4.1 CHINA 134
12.4.2 INDIA 138
12.4.3 JAPAN 142
12.4.4 SOUTH KOREA 146
12.4.5 AUSTRALIA 150
12.4.6 REST OF ASIA-PACIFIC 154
12.5 MIDDLE EAST & AFRICA 159
12.5.1 MIDDLE EAST 164
12.5.2 AFRICA 168
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW 173
13.2 COMPETITIVE BENCHMARKING 174
13.3 GLOBAL NEUROPATHIC PAIN MARKET: COMPANY RANKING, 2020 175
13.4 MAJOR GROWTH STRATEGY IN THE GLOBAL NEUROPATHIC PAIN MARKET 175
13.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 176
13.6 COMPETITIVE BENCHMARKING: GLOBAL NEUROPATHIC PAIN MARKET 176
13.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 177
13.7.1 PRODUCT APPROVALS AND LAUNCHES 177
13.7.2 ACQUISITIONS 177
13.8 FINANCIAL MATRIX 178
14 COMPANY PROFILES
14.1 ABBOTT 179
14.1.1 COMPANY OVERVIEW 179
14.1.2 FINANCIAL OVERVIEW 180
14.1.3 PRODUCTS/SERVICES OFFERED 180
14.1.4 KEY DEVELOPMENTS 181
14.1.5 SWOT ANALYSIS 182
14.1.6 KEY STRATEGIES 182
14.2 PFIZER 183
14.2.1 COMPANY OVERVIEW 183
14.2.2 FINANCIAL OVERVIEW 183
14.2.3 PRODUCTS/SERVICES OFFERED 184
14.2.4 KEY DEVELOPMENTS 184
14.2.5 SWOT ANALYSIS 184
14.2.6 KEY STRATEGIES 184
14.3 JOHNSON & JOHNSON SERVICES, INC. 185
14.3.1 COMPANY OVERVIEW 185
14.3.2 FINANCIAL OVERVIEW 186
14.3.3 PRODUCTS/SERVICES OFFERED 186
14.3.4 KEY DEVELOPMENTS 186
14.3.5 SWOT ANALYSIS 187
14.3.6 KEY STRATEGIES 187
14.4 BAXTER INTERNATIONAL 188
14.4.1 COMPANY OVERVIEW 188
14.4.2 FINANCIAL OVERVIEW 188
14.4.3 PRODUCTS/SERVICES OFFERED 189
14.4.4 KEY DEVELOPMENTS 189
14.4.5 SWOT ANALYSIS 189
14.4.6 KEY STRATEGIES 190
14.5 ELI LILY AND COMPANY 190
14.5.1 COMPANY OVERVIEW 190
14.5.2 FINANCIAL OVERVIEW 191
14.5.3 PRODUCTS/SERVICES OFFERED 191
14.5.4 KEY DEVELOPMENTS 191
14.5.5 SWOT ANALYSIS 192
14.5.6 KEY STRATEGIES 192
14.6 GLAXOSMITHKLINE PLC 193
14.6.1 COMPANY OVERVIEW 193
14.6.2 FINANCIAL OVERVIEW 193
14.6.3 PRODUCTS/SERVICES OFFERED 194
14.6.4 KEY DEVELOPMENTS 194
14.6.5 SWOT ANALYSIS 194
14.6.6 KEY STRATEGIES 195
14.7 SANOFI 195
14.7.1 COMPANY OVERVIEW 195
14.7.2 FINANCIAL OVERVIEW 196
14.7.3 PRODUCTS/SERVICES OFFERED 196
14.7.4 KEY DEVELOPMENTS 197
14.7.5 SWOT ANALYSIS 197
14.7.6 KEY STRATEGIES 197
14.8 ASTRAZENECA 198
14.8.1 COMPANY OVERVIEW 198
14.8.2 FINANCIAL OVERVIEW 198
14.8.3 PRODUCTS/SERVICES OFFERED 199
14.8.4 KEY DEVELOPMENTS 199
14.8.5 SWOT ANALYSIS 199
14.8.6 KEY STRATEGIES 199
14.9 DEPOMED INC. (ASSERTIO THERAPEUTICS, INC) 200
14.9.1 COMPANY OVERVIEW 200
14.9.2 FINANCIAL OVERVIEW 200
14.9.3 PRODUCTS/SERVICES OFFERED 200
14.9.4 KEY DEVELOPMENTS 201
14.9.5 SWOT ANALYSIS 201
14.9.6 KEY STRATEGIES 202
14.10 BIOGEN, INC. 202
14.10.1 COMPANY OVERVIEW 202
14.10.2 FINANCIAL OVERVIEW 202
14.10.3 PRODUCTS/SERVICES OFFERED 203
14.10.4 KEY DEVELOPMENTS 203
14.10.5 SWOT ANALYSIS 203
14.10.6 KEY STRATEGIES 203
14.11 ASTELLAS PHARMA LTD. 204
14.11.1 COMPANY OVERVIEW 204
14.11.2 FINANCIAL OVERVIEW 204
14.11.3 PRODUCTS/SERVICES OFFERED 205
14.11.4 KEY DEVELOPMENTS 205
14.11.5 SWOT ANALYSIS 205
14.11.6 KEY STRATEGIES 206
15 APPENDIX
15.1 REFERENCES 207
15.2 RELATED REPORTS 207
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 24
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 27
TABLE 3 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 46
TABLE 4 GLOBAL NEUROPATHIC PAIN MARKET FOR PERIPHERAL NEUROPATHY, BY REGION, 2020-2027 (USD MILLION) 47
TABLE 5 GLOBAL NEUROPATHIC PAIN MARKET FOR ENTRAPMENT NEUROPATHY, BY REGION, 2020-2027 (USD MILLION) 47
TABLE 6 GLOBAL NEUROPATHIC PAIN MARKET FOR TRIGEMINAL NEURALGIA, BY REGION, 2020-2027 (USD MILLION) 48
TABLE 7 GLOBAL NEUROPATHIC PAIN MARKET FOR PHANTOM LIMB PAIN, BY REGION, 2020-2027 (USD MILLION) 48
TABLE 8 GLOBAL NEUROPATHIC PAIN MARKET FOR POST HERPETIC NEURALGIA (PHN), BY REGION, 2020-2027 (USD MILLION) 49
TABLE 9 GLOBAL NEUROPATHIC PAIN MARKET FOR POST TRAUMATIC NEUROPATHY, BY REGION, 2020-2027(USD MILLION) 49
TABLE 10 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2029 (USD MILLION) 51
TABLE 11 GLOBAL NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY REGION 2020-2029 (USD MILLION) 52
TABLE 12 GLOBAL NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE 2020-2029 (USD MILLION) 52
TABLE 13 GLOBAL NEUROPATHIC PAIN MARKET, FOR SPINAL STENOSIS, BY REGION, 2020-2029 (USD MILLION) 52
TABLE 14 GLOBAL NEUROPATHIC PAIN MARKET, FOR CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, BY REGION 2020-2029 (USD MILLION) 53
TABLE 15 GLOBAL NEUROPATHIC PAIN MARKET, FOR OTHERS, BY REGION, 2020-2029 (USD MILLION) 53
TABLE 16 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 55
TABLE 17 GLOBAL NEUROPATHIC PAIN MARKET FOR IMAGING, BY REGION, 2020-2027 (USD MILLION) 55
TABLE 18 GLOBAL NEUROPATHIC PAIN MARKET BY IMAGING TYPE, 2020-2027 (USD MILLION) 55
TABLE 19 GLOBAL NEUROPATHIC PAIN MARKET FOR BLOOD TESTS, BY REGION, 2020-2027 (USD MILLION) 56
TABLE 20 GLOBAL NEUROPATHIC PAIN MARKET FOR PHYSICAL EXAMINATION, BY REGION, 2020-2027 (USD MILLION) 56
TABLE 21 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 58
TABLE 22 GLOBAL NEUROPATHIC PAIN MARKET FOR MEDICATION, BY REGION, 2020-2027 (USD MILLION) 58
TABLE 23 GLOBAL NEUROPATHIC PAIN MARKET BY MEDICATION TYPE, 2020-2027 (USD MILLION) 59
TABLE 24 GLOBAL NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 59
TABLE 25 GLOBAL NEUROPATHIC PAIN MARKET BY ANTIDEPRESSANT DRUGS, 2020-2027 (USD MILLION) 59
TABLE 26 GLOBAL NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 60
TABLE 27 GLOBAL NEUROPATHIC PAIN MARKET FOR MULTIMODAL THERAPY, BY REGION, 2020-2027 (USD MILLION) 60
TABLE 28 GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 62
TABLE 29 GLOBAL NEUROPATHIC PAIN MARKET FOR RETAIL PHARMACIES & DRUG STORES, BY REGION, 2020-2027 (USD MILLION) 62
TABLE 30 GLOBAL NEUROPATHIC PAIN MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2027 (USD MILLION) 62
TABLE 31 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 64
TABLE 32 GLOBAL NEUROPATHIC PAIN MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION) 64
TABLE 33 GLOBAL NEUROPATHIC PAIN MARKET FOR CLINICS, BY REGION, 2020-2027 (USD MILLION) 64
TABLE 34 GLOBAL NEUROPATHIC PAIN MARKET FOR RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION) 65
TABLE 35 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION, 2020-2027 (USD MILLION) 66
TABLE 36 AMERICAS: NEUROPATHIC PAIN MARKET, BY REGION, 2020-2027 (USD MILLION) 67
TABLE 37 AMERICAS: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 68
TABLE 38 AMERICAS: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 68
TABLE 39 AMERICAS: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 68
TABLE 40 AMERICAS: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 69
TABLE 41 AMERICAS: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 69
TABLE 42 AMERICAS: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 69
TABLE 43 AMERICAS: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 70
TABLE 44 AMERICAS: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 70
TABLE 45 AMERICAS: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 70
TABLE 46 AMERICAS: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 71
TABLE 47 AMERICAS: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 71
TABLE 48 AMERICAS: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 71
TABLE 49 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 73
TABLE 50 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 73
TABLE 51 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 73
TABLE 52 NORTH AMERICA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 74
TABLE 53 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 74
TABLE 54 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 74
TABLE 55 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY TREATMENT,2020-2027 (USD MILLION) 75
TABLE 56 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 75
TABLE 57 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 75
TABLE 58 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 76
TABLE 59 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 76
TABLE 60 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 76
TABLE 61 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 77
TABLE 62 US: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 77
TABLE 63 US: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 77
TABLE 64 US: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 78
TABLE 65 US: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 78
TABLE 66 US: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 78
TABLE 67 US: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 79
TABLE 68 US: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 79
TABLE 69 US: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 79
TABLE 70 US: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 80
TABLE 71 US: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 80
TABLE 72 US: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 80
TABLE 73 US: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 81
TABLE 74 CANADA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 81
TABLE 75 CANADA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 81
TABLE 76 CANADA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 82
TABLE 77 CANADA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 82
TABLE 78 CANADA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 82
TABLE 79 CANADA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 83
TABLE 80 CANADA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 83
TABLE 81 CANADA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 83
TABLE 82 CANADA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 84
TABLE 83 CANADA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 84
TABLE 84 CANADA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 84
TABLE 85 CANADA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 85
TABLE 86 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION), 85
TABLE 87 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 85
TABLE 88 LATIN AMERICA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 86
TABLE 89 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 86
TABLE 90 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 86
TABLE 91 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 87
TABLE 92 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 87
TABLE 93 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 87
TABLE 94 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 88
TABLE 95 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 88
TABLE 96 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 88
TABLE 97 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 89
TABLE 98 EUROPE: NEUROPATHIC PAIN MARKET, BY REGION, 2020-2027 (USD MILLION) 90
TABLE 99 EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 91
TABLE 100 EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 91
TABLE 101 EUROPE: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 91
TABLE 102 EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 92
TABLE 103 EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 92
TABLE 104 EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 92
TABLE 105 EUROPE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 93
TABLE 106 EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 93
TABLE 107 EUROPE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 93
TABLE 108 EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 94
TABLE 109 EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 94
TABLE 110 EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 94
TABLE 111 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 95
TABLE 112 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 96
TABLE 113 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 96
TABLE 114 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 97
TABLE 115 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 97
TABLE 116 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 97
TABLE 117 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 98
TABLE 118 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 98
TABLE 119 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 98
TABLE 120 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 99
TABLE 121 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 99
TABLE 122 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 99
TABLE 123 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 100
TABLE 124 GERMANY NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 100
TABLE 125 GERMANY: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 100
TABLE 126 GERMANY: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 101
TABLE 127 GERMANY: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 101
TABLE 128 GERMANY: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 101
TABLE 129 GERMANY: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 102
TABLE 130 GERMANY: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 102
TABLE 131 GERMANY: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 102
TABLE 132 GERMANY: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 103
TABLE 133 GERMANY: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 103
TABLE 134 GERMANY: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 103
TABLE 135 GERMANY: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 104
TABLE 136 UK: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 104
TABLE 137 UK: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 104
TABLE 138 UK: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 105
TABLE 139 UK: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 105
TABLE 140 UK: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 105
TABLE 141 UK: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 106
TABLE 142 UK: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 106
TABLE 143 UK: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 106
TABLE 144 UK: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 107
TABLE 145 UK: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 107
TABLE 146 UK: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 107
TABLE 147 UK: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 108
TABLE 148 FRANCE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 108
TABLE 149 FRANCE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 108
TABLE 150 FRANCE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 109
TABLE 151 FRANCE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 109
TABLE 152 FRANCE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 109
TABLE 153 FRANCE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 110
TABLE 154 FRANCE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 110
TABLE 155 FRANCE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 110
TABLE 156 FRANCE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 111
TABLE 157 FRANCE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 111
TABLE 158 FRANCE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 111
TABLE 159 FRANCE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 112
TABLE 160 ITALY: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 112
TABLE 161 ITALY: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 112
TABLE 162 ITALY: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 113
TABLE 163 ITALY: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 113
TABLE 164 ITALY: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 113
TABLE 165 ITALY: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 114
TABLE 166 ITALY: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 114
TABLE 167 ITALY: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 114
TABLE 168 ITALY: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 115
TABLE 169 ITALY: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 115
TABLE 170 ITALY: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 115
TABLE 171 ITALY: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 116
TABLE 172 SPAIN: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 116
TABLE 173 SPAIN: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 116
TABLE 174 SPAIN: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 117
TABLE 175 SPAIN: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 117
TABLE 176 SPAIN: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 117
TABLE 177 SPAIN: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 118
TABLE 178 SPAIN: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 118
TABLE 179 SPAIN: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 118
TABLE 180 SPAIN: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 119
TABLE 181 SPAIN: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 119
TABLE 182 SPAIN: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 119
TABLE 183 SPAIN: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 120
TABLE 184 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 120
TABLE 185 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 120
TABLE 186 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 121
TABLE 187 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 121
TABLE 188 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 121
TABLE 189 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 122
TABLE 190 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 122
TABLE 191 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 122
TABLE 192 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 123
TABLE 193 REST OF WESTERN EUROPE” NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 123
TABLE 194 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 123
TABLE 195 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 124
TABLE 196 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 124
TABLE 197 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 125
TABLE 198 EASTERN EUROPE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 125
TABLE 199 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 125
TABLE 200 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 126
TABLE 201 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 126
TABLE 202 EASTERN EUROPE NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 126
TABLE 203 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 127
TABLE 204 EASTERN EUROPE NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 127
TABLE 205 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 127
TABLE 206 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 128
TABLE 207 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 128
TABLE 208 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 129
TABLE 209 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 130
TABLE 210 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 130
TABLE 211 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 131
TABLE 212 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 131
TABLE 213 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 131
TABLE 214 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 132
TABLE 215 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 132
TABLE 216 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 132
TABLE 217 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 133
TABLE 218 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 133
TABLE 219 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 133
TABLE 220 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 134
TABLE 221 CHINA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 134
TABLE 222 CHINA NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 134
TABLE 223 CHINA NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 135
TABLE 224 CHINA NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 135
TABLE 225 CHINA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 135
TABLE 226 CHINA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 136
TABLE 227 CHINA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 136
TABLE 228 CHINA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 136
TABLE 229 CHINA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 137
TABLE 230 CHINA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 137
TABLE 231 CHINA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 137
TABLE 232 CHINA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 138
TABLE 233 INDIA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 138
TABLE 234 INDIA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 138
TABLE 235 INDIA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 139
TABLE 236 INDIA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 139
TABLE 237 INDIA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 139
TABLE 238 INDIA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 140
TABLE 239 INDIA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 140
TABLE 240 INDIA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 140
TABLE 241 INDIA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 141
TABLE 242 INDIA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 141
TABLE 243 INDIA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 141
TABLE 244 INDIA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 142
TABLE 245 JAPAN: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 142
TABLE 246 JAPAN: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 142
TABLE 247 JAPAN: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 143
TABLE 248 JAPAN: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 143
TABLE 249 JAPAN: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 143
TABLE 250 JAPAN: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 144
TABLE 251 JAPAN: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 144
TABLE 252 JAPAN: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 144
TABLE 253 JAPAN: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 145
TABLE 254 JAPAN: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 145
TABLE 255 JAPAN: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 145
TABLE 256 JAPAN: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 146
TABLE 257 SOUTH KOREA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 146
TABLE 258 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 146
TABLE 259 SOUTH KOREA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 147
TABLE 260 SOUTH KOREA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 147
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 21
FIGURE 2 GLOBAL NEUROPATHIC PAIN MARKET 23
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 30
FIGURE 4 MARKET DYNAMICS: NEUROPATHIC PAIN MARKET 33
FIGURE 5 DRIVER IMPACT ANALYSIS 36
FIGURE 6 RESTRAINT IMPACT ANALYSIS 38
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL NEUROPATHIC PAIN MARKET 39
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NEUROPATHIC PAIN MARKET 41
FIGURE 9 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 46
FIGURE 10 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2020 AND 2027 (USD MILLION) 51
FIGURE 11 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020 AND 2027 (USD MILLION) 54
FIGURE 12 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020 AND 2027 (USD MILLION) 58
FIGURE 13 GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020 AND 2027 (USD MILLION) 61
FIGURE 14 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 63
FIGURE 15 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 66
FIGURE 16 AMERICAS: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 67
FIGURE 17 NORTH AMERICA: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 72
FIGURE 18 EUROPE: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 90
FIGURE 19 WESTERN EUROPE: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 95
FIGURE 20 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 129
FIGURE 21 MIDDLE EAST & AFRICA: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 159
FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS 174
FIGURE 23 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL NEUROPATHIC PAIN MARKET 175
FIGURE 24 COMPETITIVE BENCHMARKING 176
FIGURE 25 SALES & OPERATING INCOME MARGIN, 2020 178
FIGURE 26 RESEARCH & DEVELOPMENT EXPENDITURE, 2020 178
FIGURE 27 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 180
FIGURE 28 ABBOTT: SWOT ANALYSIS 182
FIGURE 29 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 183
FIGURE 30 PFIZER INC.: SWOT ANALYSIS 184
FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 186
FIGURE 32 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 187
FIGURE 33 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW 188
FIGURE 34 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS 189
FIGURE 35 ELI LILY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 191
FIGURE 36 ELI LILY AND COMPANY: SWOT ANALYSIS 192
FIGURE 37 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 193
FIGURE 38 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 194
FIGURE 39 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 196
FIGURE 40 SANOFI: SWOT ANALYSIS 197
FIGURE 41 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 198
FIGURE 42 ASTRAZENECA: SWOT ANALYSIS 199
FIGURE 43 DEPOMED, INC.: FINANCIAL OVERVIEW SNAPSHOT 200
FIGURE 44 DEPOMED, INC.: SWOT ANALYSIS 201
FIGURE 45 BIOGEN, INC.: FINANCIAL OVERVIEW SNAPSHOT 202
FIGURE 46 BIOGEN: SWOT ANALYSIS 203
FIGURE 47 ASTELLAS PHARMA LTD.: FINANCIAL OVERVIEW SNAPSHOT 204
FIGURE 48 ASTELLAS PHARMA: SWOT ANALYSIS 205